Inhibition of glucagon secretion (Q36402843)

14 August 2017

1 reference

title

Inhibition of glucagon secretion (English)

1 reference

14 August 2017

1 reference

Andrew Young

1 reference

14 August 2017

publication date

1 January 2005

1 reference

14 August 2017

published in

Advances in Pharmacology

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

151-171

1 reference

Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Glucagon: Role in the Hyperglycemia of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Dose-response for glucagonostatic effect of amylin in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

1 reference

7 January 2021

Effects of amylin on the release of insulin and glucagon from the perfused rat pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

The mechanism of exaggerated glucagon response to arginine in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Method for the Isolation of Intact Islets of Langerhans from the Rat Pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Bulk cryopreservation of isolated islets of Langerhans

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Insulin within islets is a physiologic glucagon release inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Insulin and glucagon secretion in rats: effects of calcitonin gene-related peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Glucagon and Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Abnormal alpha cell function in human diabetes: the response to oral protein

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

The microanatomy of canine islets of Langerhans: implications for intra-islet regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Intra-islet insulin-glucagon-somatostatin relationships

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Effect of Calcitonin on plasma glucose, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Somatostatin, insulin and glucagon secretion by the perfused pancreas from the cysteamine-treated rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Effect of (8-32) salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: study in the perfused pancreas of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Effects of calcium and calcitonin on circulating levels of glucagon and glucose in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Role of glucagon in the pathogenesis of diabetes: The status of the controversy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Glucagon physiology and pathophysiology in the light of new advances

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Studies of pancreatic alpha cell function in normal and diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Islets of Langerhans: the puzzle of intraislet interactions and their relevance to diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

Amylin injection causes elevated plasma lactate and glucose in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2805%2952008-8

7 January 2021

10.1016/S1054-3589(05)52008-8

Identifiers

DOI

1 reference

14 August 2017

1 reference